Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9471405 | 0.84 | ALDH1A1 (0.61) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL7364286 | 0.84 | ALDH1A1 (0.50) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL9471179 | 0.84 | ALDH1A1 (0.51) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL9471594 | 0.84 | TRPM8 (0.52) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL15667384 | 0.82 | ALDH1A1 (0.47) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL30966332 | 0.81 | ALDH1A1 (0.68) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL22170060 | 0.79 | ALDH1A1 (0.65) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL10521334 | 0.79 | ALDH1A1 (0.65) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL10521343 | 0.79 | ALDH1A1 (0.65) | ALDH1A1NPSR1NPC1HTTRAB9A | |
| SCHEMBL4294754 | 0.78 | KMT2A (0.54) | NPSR1NPC1RAB9APOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | claimed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0473687-B1 | STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER | DU PONT MERCK PHARMA (US) | 1996-03-27 | — | — | EP | claimed |
| EP-0473687-A4 | STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER | DU PONT MERCK PHARMA (US) | 1992-12-02 | — | — | EP | claimed |
| EP-0473687-A1 | STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER. | DU PONT MERCK PHARMA (US) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014080-A1 | STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-11-29 | — | — | WO | claimed |
| US-4925860-A | ANTICONVULSANTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| CN-118161457-A | Solid composition of fosphenytoin sodium, freeze-drying method and application thereof | 四川科瑞德制药股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114588116-B | Solid composition of fosphenytoin sodium, freeze-drying method and application thereof | 四川科瑞德制药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240033223-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | FIDELITY BIOPHARMA CO. | 2024-02-01 | — | — | US | disclosed |
| CN-117269494-A | A group of metabolic markers for breast cancer lung metastasis | 厦门大学 | 2023-12-22 | — | — | CN | disclosed |
| EP-4257120-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | Sichuan Credit Pharmaceutical Co., Ltd (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022116134-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | 四川科瑞德制药股份有限公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-0427925-A2 | Use of prophenytoin for preparing pharmaceutical preparations for treating stroke and cerebral ischemia | WARNER-LAMBERT COMPANY (US) | 1991-05-22 | — | — | EP | disclosed |
| WO-1990014080-A1 | STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-11-29 | — | — | WO | disclosed |
| WO-1990014080-A1 | STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-11-29 | — | — | WO | disclosed |
| US-4925860-A | ANTICONVULSANTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-15 | — | — | US | disclosed |
| US-4925860-A | ANTICONVULSANTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-15 | — | — | US | disclosed |
| US-4402949-A | ANTI-THROMBOTIC AGENTS, POST-OPERATIVE PROPHYLAXIS | SANDOZ LTD. (CH) | 1983-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033223-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | FOS, CA3, SORD | ALDH1A1 4283/4885NPSR1 1147/4885NPC1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.